Compare · DXCM vs NXGL
DXCM vs NXGL
Side-by-side comparison of DexCom Inc. (DXCM) and NexGel Inc (NXGL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NXGL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 6801.3x NXGL ($4.3M).
- Over the past year, DXCM is down 8.6% and NXGL is down 81.6% - DXCM leads by 73.0 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 3 for NXGL).
- DXCM has more recent analyst coverage (25 ratings vs 1 for NXGL).
- Company
- DexCom Inc.
- NexGel Inc
- Price
- $76.65-1.74%
- $0.44+1.32%
- Market cap
- $29.58B
- $4.3M
- 1M return
- +4.76%
- -19.29%
- 1Y return
- -8.64%
- -81.61%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 6
- 3
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
NexGel Inc
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest NXGL
- SEC Form 8-K filed by NexGel Inc
- SEC Form 8-K filed by NexGel Inc
- Chief Executive Officer Levy Adam R. sold $6,519 worth of shares (11,000 units at $0.59), decreasing direct ownership by 3% to 322,692 units (SEC Form 4)
- NexGel Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Executive Officer Levy Adam R. sold $1,841 worth of shares (3,000 units at $0.61), decreasing direct ownership by 0.89% to 333,692 units (SEC Form 4)
- Chief Executive Officer Levy Adam R. sold $3,422 worth of shares (6,000 units at $0.57), decreasing direct ownership by 2% to 336,692 units (SEC Form 4)
- SEC Form DEF 14A filed by NexGel Inc
- NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
- Chief Executive Officer Levy Adam R. sold $1,172 worth of shares (2,000 units at $0.59), decreasing direct ownership by 0.58% to 342,692 units (SEC Form 4)
- Chief Executive Officer Levy Adam R. sold $7,834 worth of shares (13,000 units at $0.60), decreasing direct ownership by 4% to 344,692 units (SEC Form 4)